# Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients

> **NCT00424606** · PHASE3 · COMPLETED · sponsor: **Hellenic Oncology Research Group** · enrollment: 658 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Epirubicin
- **DRUG:** Epirubicin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00424606
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 658 (ACTUAL)
- **Last updated:** 2015-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424606, "Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00424606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*